Mechanisms of resistance to TRAIL-induced apoptosis in cancer

The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is regarded as a potential anticancer agent. However, considerable numbers of cancer cells, especially some highly malignant tumors, are resistant to apoptosis induction by TRAIL, and some cancer cells that were originally sensitive to TRAIL-induced apoptosis can become resistant after repeated exposure (acquired resistance). Understanding the mechanisms underlying such resistance and developing strategies to overcome it are important for the successful use of TRAIL for cancer therapy. Resistance to TRAIL can occur at different points in the signaling pathways of TRAIL-induced apoptosis. Dysfunctions of the death receptors DR4 and DR5 due to mutations can lead to resistance. The adaptor protein Fas-associated death domain (FADD) and caspase-8 are essential for assembly of the death-inducing signaling complex, and defects in either of these molecules can lead to TRAIL resistance. Overexpression of cellular FADD-like interleukin-1β-converting enzyme-inhibitory protein (cFLIP) correlates with TRAIL resistance in several types of cancer. Overexpression of Bcl-2 or Bcl-XL, loss of Bax or Bak function, high expression of inhibitor of apoptosis proteins, and reduced release of second mitochondria-derived activator of caspases (Smac/Diablo) from the mitochondria to the cytosol have all been reported to result in TRAIL resistance in mitochondria-dependent type II cancer cells. Finally, activation of different subunits of mitogen-activated protein kinases or nuclear factor-kappa B can lead to development of either TRAIL resistance or apoptosis in certain types of cancer cells.

[1]  岡野 宏.  Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma , 2003 .

[2]  P. Hersey,et al.  Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria , 2003, Oncogene.

[3]  J. Tschopp,et al.  Inhibition of Death Receptor Signaling by Flice-Inhibitory Protein as a Mechanism for Immune Escape of Tumors , 1999, The Journal of experimental medicine.

[4]  L. Hood,et al.  Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. , 1997, Immunity.

[5]  Martin Schenk,et al.  Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. , 2003, Cancer research.

[6]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[7]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[8]  H. S. Kim,et al.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. , 2001, Cancer research.

[9]  S. Shankar,et al.  Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  J. Tschopp,et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.

[11]  Min Goo Lee,et al.  Increased expression of cFLIPL in colonic adenocarcinoma , 2001 .

[12]  R. Gentz,et al.  I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[13]  H. Chun,et al.  Caspase-10 is an initiator caspase in death receptor signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  B. Bonavida,et al.  X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-bi , 2002, Molecular cancer therapeutics.

[15]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[16]  P. Secchiero,et al.  Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. , 2003, Journal of leukocyte biology.

[17]  N. Spinner,et al.  Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. , 2000, International journal of oncology.

[18]  J. Tschopp,et al.  FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. , 1998, Journal of immunology.

[19]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[20]  H. Ichijo,et al.  From receptors to stress-activated MAP kinases , 1999, Oncogene.

[21]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[22]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[24]  S. Fulda,et al.  Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer , 2001, Oncogene.

[25]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[26]  H. S. Kim,et al.  Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. , 1999, Cancer research.

[27]  Y. Jeng,et al.  Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. , 2002, Cancer letters.

[28]  R. Kimberly,et al.  Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway , 2003, Oncogene.

[29]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[30]  Marc Nasoff,et al.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.

[31]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[32]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[33]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[34]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[35]  P. Scheurich,et al.  Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction , 1998, Current Biology.

[36]  J. Gu,et al.  Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line , 2002, Gene Therapy.

[37]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[38]  Y. Goltsev,et al.  CASH, a Novel Caspase Homologue with Death Effector Domains* , 1997, The Journal of Biological Chemistry.

[39]  J. Tschopp,et al.  Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells , 2003, Oncogene.

[40]  H. Kalthoff,et al.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis , 2000, Oncogene.

[41]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[42]  J. Puck,et al.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency , 2002, Nature.

[43]  J. Tschopp,et al.  Selective expression of FLIP in malignant melanocytic skin lesions. , 2001, The Journal of investigative dermatology.

[44]  J. Jen,et al.  Rare loss-of-function mutation of a death receptor gene in head and neck cancer. , 1998, Cancer research.

[45]  R. Watson,et al.  Defining a role for the inhibitors of apoptosis proteins in prostate cancer , 2001, Prostate Cancer and Prostatic Diseases.

[46]  J. Gu,et al.  A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo , 2002, Oncogene.

[47]  B. Trask,et al.  MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. Krammer,et al.  Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex* , 2001, The Journal of Biological Chemistry.

[49]  P. Hersey,et al.  Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types , 2000, FEBS letters.

[50]  B. Vandenbunder,et al.  Rel/NF-κB Transcription Factors Protect against Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Up-regulating the TRAIL Decoy Receptor DcR1* , 2001, The Journal of Biological Chemistry.

[51]  P. Daniel,et al.  The kiss of death: promises and failures of death receptors and ligands in cancer therapy , 2001, Leukemia.

[52]  J. Bertin,et al.  Death-effector Filaments: Novel Cytoplasmic Structures that Recruit Caspases and Trigger Apoptosis , 1998, The Journal of cell biology.

[53]  N. K. Sah,et al.  Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase* , 2003, Journal of Biological Chemistry.

[54]  A. Grosse-Wilde,et al.  Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8 , 2002, The EMBO journal.

[55]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[56]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.

[57]  P. Secchiero,et al.  Tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) and TNF‐α promote the NF‐κB‐dependent maturation of normal and leukemic myeloid cells , 2003 .

[58]  J. Houghton,et al.  A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells , 2003, Cell Death and Differentiation.

[59]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[60]  Amnon Zisman,et al.  Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL‐mediated apoptosis of prostate cancer cells: Role of XIAP in resistance , 2002, The Prostate.

[61]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[62]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[63]  John Calvin Reed,et al.  PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2 , 2003, Oncogene.

[64]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[65]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[66]  R. Schwabe,et al.  TRAIL‐mediated apoptosis requires NF‐kB inhibition and the mitochondrial permeability transition in human hepatoma cells , 2002 .

[67]  M. Hayden,et al.  Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex , 1998, Cell Death and Differentiation.

[68]  S. Korsmeyer,et al.  Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. , 2003, Cancer research.

[69]  S. Chi,et al.  Increased expression of cFLIP(L) in colonic adenocarcinoma. , 2001, The Journal of pathology.

[70]  D. Goeddel,et al.  Casper is a FADD- and caspase-related inducer of apoptosis. , 1997, Immunity.

[71]  M. Seldin,et al.  Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. , 1999, Blood.

[72]  E. Henson,et al.  Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines , 2002, Apoptosis.

[73]  Robert L Moritz,et al.  Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins , 2000, Cell.

[74]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[75]  A. Gambotto,et al.  A Role for Mitochondrial Bak in Apoptotic Response to Anticancer Drugs* , 2001, The Journal of Biological Chemistry.

[76]  B. Fang,et al.  Lack of p38 MAP Kinase Activation in TRAIL-Resistant Cells is Not Related to the Resistance to TRAIL-Mediated Cell Death , 2004, Cancer biology & therapy.

[77]  P. Krammer,et al.  FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis , 2001, Molecular and Cellular Biology.

[78]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[80]  M. Shin,et al.  Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma , 2001, Oncogene.

[81]  Alnawaz Rehemtulla,et al.  TRAIL and Anti-Tumor Responses , 2003, Cancer biology & therapy.

[82]  R. K Srivastava,et al.  Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. , 2003, Cancer research.

[83]  E. Henson,et al.  Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. , 2002, Apoptosis : an international journal on programmed cell death.

[84]  D. Seol,et al.  Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. , 2001, Cancer research.

[85]  C. Thompson,et al.  A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. , 1996, The EMBO journal.

[86]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[87]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[88]  A. Winoto,et al.  FADD Is Required for DR4- and DR5-mediated Apoptosis , 2000, The Journal of Biological Chemistry.

[89]  T. Griffith,et al.  Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. , 1998, Journal of immunology.

[90]  S. Srinivasula,et al.  FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[91]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[92]  Steven A Curley,et al.  Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.

[93]  C. Thiele,et al.  Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB. , 2003, Cancer Research.

[94]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[95]  S. Chen,et al.  CLARP, a death effector domain-containing protein interacts with caspase-8 and regulates apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[97]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[98]  G. Cohen,et al.  Modulation of Tumor Necrosis Factor Apoptosis-inducing Ligand- induced NF-κB Activation by Inhibition of Apical Caspases* , 2001, The Journal of Biological Chemistry.

[99]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.